prior to diagnosis (4.4 ± 0.6 years for those diagnosed after 1993 compared to 9.0 ± 1.1 years forthose diagnosed prior to 1993, p
References1. Green PH, Jabri B. Coeliac disease. Lancet. 2003;362:383–391.2. Murray JA, Van Dyke C, Plevak MF, Dierkhising RA, Zinsmeister AR, Melton LJ 3rd.Trends in the identification and clinical features of celiac disease in a North Americancommunity, 1950–2001. Clin Gastroenterol Hepatol. 2003;1:19–27.3. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-riskgroups in the United States: a large multicenter study. Arch Intern Med. 2003;163:286–292.4. West J, Logan RF, Hill PG, et al. Seroprevalence, correlates, and characteristics ofundetected coeliac disease in England. Gut. 2003;52:960–965.5. Green PHR, Stavropoulos SN, Panagi SG et al. Characteristics of adult celiac disease in theUSA: results of a national survey. Am J Gastroenterol. 2001;96:126–131.6. Lankisch PG, Martinez Schramm A, Petersen F, Droge M, Lehnick D, Lembcke B.Diagnostic intervals for recognizing celiac disease. Z Gastroenterol. 1996;34:473–477.7. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease withirritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referredto secondary care. Lancet. 2001;358:1504–1508.8. Lo W, Sano K, Lebwohl B, Diamond B, Green PH. Changing presentation of adult celiacdisease. Dig Dis Sci. 2003;48:395–398.9. Green PH, Shane E, Rotterdam H, Forde KA, Grossbard L. Significance of unsuspectedceliac disease detected at endoscopy. Gastrointest Endosc. 2000;51:60–65.10. Bardella MT, Minoli G, Ravizza D, et al. Increased prevalence of celiac disease in patientswith dyspepsia. Arch Intern Med. 2000;160:1489–1491.11. Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of malignancy inpatients with celiac disease. Am J Med. 2003;115:191–195.12. Rampertab SD, Forde KA, Green PH. Small bowel neoplasia in coeliac disease. Gut.2003;52:1211–1214.13. Alaedini A, Green PH, Sander HW, et al. Ganglioside reactive antibodies in the neuropathyassociated with celiac disease. J Neuroimmunol. 2002;127:145–148.14. Rabsztyn A, Green PH, Berti I, Fasano A, Perman JA, Horvath K. Macroamylasemia inpatients with celiac disease. Am J Gastroenterol. 2001;96:1096–1100.15. Dahele A, Kingstone K, Bode J, Anderson D, Ghosh S. Anti-endomysial antibody-negativeceliac disease: does additional serological testing help? Dig Dis Sci. 2001;46:214–221.67
- Page 1 and 2:
NIH Consensus Development Conferenc
- Page 3 and 4:
III. What Are the Manifestations an
- Page 5 and 6:
• What is the management of celia
- Page 7 and 8: Monday, June 28, 2004 (continued)I.
- Page 9 and 10: Monday, June 28, 2004 (continued)II
- Page 11 and 12: Wednesday, June 30, 2004 (continued
- Page 13 and 14: Lisa H. RichardsonConsumer Represen
- Page 15 and 16: Ciaran P. Kelly, M.D.Director, Celi
- Page 17 and 18: Van S. Hubbard, M.D., Ph.D.Director
- Page 19 and 20: AbstractsThe following are abstract
- Page 21 and 22: susceptibility (e.g., DR17 homozygo
- Page 23 and 24: The Pathology of Celiac DiseaseDavi
- Page 25 and 26: In this regard, the transport pathw
- Page 27 and 28: for the IgG-based test, while speci
- Page 29 and 30: 15. de Lecea A, Ribes-Koninckx C, P
- Page 31 and 32: Clinical Algorithm in Celiac Diseas
- Page 33 and 34: Considera diagnosisof celiac diseas
- Page 35 and 36: There are populations at particular
- Page 37 and 38: Serological Testing for Celiac Dise
- Page 39 and 40: Estimates of the sensitivity of the
- Page 41 and 42: the risk and severity of CD may als
- Page 43 and 44: What Are the Prevalence and Inciden
- Page 45 and 46: ascribed to excess menstrual loss.
- Page 47 and 48: ReferencesFamily History of Celiac
- Page 49 and 50: Carroccio A, Iannitto E, Cavataio F
- Page 51 and 52: identified by surveys or through so
- Page 53 and 54: Clinical Presentation of Celiac Dis
- Page 55 and 56: een widely reported. The question r
- Page 57: The Many Faces of Celiac Disease: C
- Page 61 and 62: Association of Celiac Disease and G
- Page 63 and 64: Does the Gluten-Free Diet Protect F
- Page 65 and 66: Skin Manifestations of Celiac Disea
- Page 67 and 68: allow a better understanding of the
- Page 69 and 70: 4. Henriksson KG, Hallert C, Walan
- Page 71 and 72: characterized, clinically-identifie
- Page 73 and 74: 10. Hoffenberg EJ, Emery LM, Barrig
- Page 75 and 76: ataxia, epilepsy with posterior cer
- Page 77 and 78: Consequences of Testing for Celiac
- Page 79 and 80: Osteoporosis/FracturesThere were 11
- Page 81 and 82: Dietary Guidelines for Celiac Disea
- Page 85 and 86: 21. Thompson T. Thiamin, riboflavin
- Page 88 and 89: In order to effectively counsel ind
- Page 90 and 91: 9. Hallert C, Granno C, Hulten S, M
- Page 92 and 93: adhered to the GFD after more than
- Page 94 and 95: Patient education, close supervisio
- Page 96: 26. Mustalahti K, Lohiniemi S, Laip
Change language